Mazdutide (5mg)

What is Mazdutide (5mg)?

Mazdutide is a synthetic peptide-based investigational compound studied in metabolic research. It is designed as a dual agonist at GLP-1 and glucagon receptors (GLP-1R/GCGR), derived from the gut hormone oxyntomodulin. This peptide influences incretin-related hormonal signaling pathways, playing roles in metabolic regulation, energy balance, and nutrient processing. Researchers study Mazdutide in experimental models to understand how it interacts with these key pathways in controlled settings. Laboratory-grade Mazdutide is typically produced with ≥98% purity, verified by high-performance liquid chromatography (HPLC) and mass spectrometry (MS). The peptide has been investigated in preclinical and clinical research exploring metabolic pathways and endocrine peptide signaling.

What are the key features of Mazdutide (5mg)?

Mazdutide (5mg) is supplied as a lyophilized peptide powder intended for controlled laboratory studies. As an engineered dual GLP-1 and glucagon receptor agonist, it is commonly used in experimental research investigating metabolic signaling and endocrine regulation. Key features of Mazdutide (5mg) include:

• Peptide class: Synthetic dual GLP-1 and glucagon receptor agonist
• CAS Number: 2259884-03-0
• Subcategory: Weight Loss & Metabolic Peptides
• Chemical Formula: C₂₁₀H₃₂₂N₄₆O₆₇
• Peptide Sequence: His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys-{AEEA-AEEA-γGlu-γEicosanedioic acid}-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH2
• Molecular weight: 4563.06 g/mol
• Purity: Typically ≥98%, verified through HPLC analysis
• Analytical confirmation: Mass spectrometry (MS) testing
• Format: Sterile lyophilized powder supplied in a research vial

For laboratory research use only.

How is Mazdutide (5mg) synthesized?

Mazdutide is produced using solid-phase peptide synthesis (SPPS), a standard method for constructing peptides with precise amino acid sequences. In SPPS, individual amino acids are sequentially attached to a solid resin support. Protective groups guide the reaction to ensure that each amino acid binds in the correct order, forming the intended peptide chain. After synthesis, the peptide is purified by high-performance liquid chromatography (HPLC) to remove incomplete peptide fragments and impurities. Structural confirmation is then performed using mass spectrometry (MS) to verify the peptide’s molecular weight and composition. Once purified, Mazdutide is lyophilized to minimize degradation and facilitate handling in the laboratory.

What is Mazdutide (5mg) being studied for? What are its possible benefits?

Mazdutide has been studied in research focused on metabolic physiology and endocrine signaling. Designed as a dual agonist at GLP-1 and glucagon receptors, it is investigated for its potential role in regulating energy balance, glucose metabolism, and lipid regulation in experimental systems. Scientific literature has also examined how incretin-based peptide analogs like Mazdutide may influence appetite signaling, metabolic efficiency, and hormone-mediated cellular responses. These areas remain under investigation in both preclinical models and controlled clinical research settings. Current research aims to understand how engineered peptides like Mazdutide interact with complex metabolic pathways and regulatory systems within the body.

How does Mazdutide (5mg) work in research studies?

In research settings, Mazdutide is studied for its potential to modulate metabolic signaling pathways associated with incretin hormones. These pathways coordinate communication among the digestive organs, metabolic tissues, and endocrine signaling systems. Scientists study how peptide analogs like Mazdutide may affect biochemical signals that regulate metabolic processes. Experimental models often examine how the peptide interacts with cellular mechanisms involved in nutrient sensing, energy regulation, and hormone-mediated signaling pathways. Through laboratory and animal studies, researchers observe changes in metabolic markers and signaling responses. These findings contribute to a broader understanding of peptide-based metabolic regulators but remain part of ongoing scientific investigation.

What dosing information exists for Mazdutide (5mg)?

Dosing information for Mazdutide is primarily derived from preclinical research and clinical trial protocols examining incretin-based peptides. In animal studies, compounds within this peptide class have been evaluated at doses ranging from micrograms to milligrams per kilogram of body weight, depending on study design and research objectives. In laboratory experiments, Mazdutide may be tested across varying concentrations to assess biological responses in cell systems or experimental models. These concentrations differ between research protocols, and dosing parameters are established according to the goals of individual studies. There are no established human dosing guidelines for research-grade Mazdutide products.

How should Mazdutide (5mg) be stored and handled?

Lyophilized Mazdutide should typically be stored at –20 °C in a controlled laboratory environment to minimize degradation and protect peptide structural integrity. The compound should be protected from light, moisture, and excessive heat. Once reconstituted using an appropriate sterile laboratory solvent, the peptide solution is generally stored at 2–8 °C for short-term laboratory use. Researchers should avoid repeated freeze-thaw cycles because they may compromise peptide stability. Peptide integrity may vary depending on storage conditions, solvent compatibility, and laboratory handling procedures.

Where can I read more research about Mazdutide (5mg)?

Researchers interested in Mazdutide and related incretin peptide research can consult several scientific databases and journals that publish studies on metabolic regulation and peptide signaling. Examples of credible research sources include:

1. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289. Published 2023 Dec 14. doi:10.1038/s41467-023-44067-4
2. Ji L, Jiang H, An P, et al. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 2021;39:101088. Published 2021 Aug 13. doi:10.1016/j.eclinm.2021.101088
3. Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017;127(12):4217-4227. doi:10.1172/JCI97233
4. National Center for Biotechnology Information. PubChem Compound Summary for CID 167312357, Mazdutide. https://pubchem.ncbi.nlm.nih.gov/compound/Mazdutide

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.